Skip to content

EV / sales at other companies

IAR
Integra LifeSciencesIART
1.5×-0.6×
Organogenesis Holdings Inc. logo
Organogenesis Holdings Inc.ORGO
0.5×-0.5×
Artivion logo
ArtivionAORT
4.3×+0.8×
Solventum logo
SolventumSOLV
-0.5×
Vericel logo
VericelVCEL
5.6×-3.9×
Enovis logo
EnovisENOV
1.2×-0.5×

Other financials

Income statement

See full
Revenue$59.0M-33.1%
Gross profit$41.6M-41.9%
Operating income-$16.0M-295%
Net income-$10.9M-255%
EPS (diluted)-$0.07-240%

Balance sheet

See full
Cash & equivalents$159.8M+50.1%
Total debt$17.6M-5.7%
Total equity$242.9M+19.8%
Total assets$308.7M+14.1%

Cash flow

See full
Operating cash flow$1.9M-64.5%
CapEx$570.0K+51.2%
Free cash flow$1.3M-73.4%

Valuation

See full
Market cap$567.48M-33.9%
Enterprise value$425.3M-44.8%
P/E18.5×-2.9×
P/S1.5×-1.0×

Profitability

See full
Gross margin81%-0.9pp
Operating margin10.2%-5.1pp
Net margin7.9%-3.5pp
FCF margin17.8%-0.5pp

Returns & leverage

See full
Return on equity13.8%-8.6pp
Debt / equity0.1×0.0×
Current ratio5.4×+0.7×

Where this comes from

Calculated from MiMedx Group’s reported figures.

Based on the most recent quarter.

The official record: MiMedx Group’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about MiMedx Group's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MiMedx Group's EV / sales?
MiMedx Group (MDXG) reported EV / sales of 1.1× in Q1 2026.
How has MiMedx Group's EV / sales changed year-over-year?
MiMedx Group's EV / sales decreased by 61.0% year-over-year, from 2.9× to 1.1×.
What is the long-term trend for MiMedx Group's EV / sales?
Over 5 years (2020 to 2025), MiMedx Group's EV / sales has grown at a -12.2% compound annual growth rate (CAGR), from 3.9× to 2.1×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.